LON:ERGO Ergomed (ERGO) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ergomed Stock (LON:ERGO) Get Ergomed alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume280,999 shsAverage Volume346,578 shsMarket Capitalization£701.00 millionP/E Ratio4,641.38Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom. Read More Receive ERGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERGO Stock News HeadlinesAktuelle Empfehlungen zur ERGOMEDJanuary 20, 2025 | finanznachrichten.deErgomedcro Unveils New Pune Office, Reinforcing Commitment to Global GrowthOctober 12, 2024 | markets.businessinsider.comRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 14 at 1:00 AM | Porter & Company (Ad)Icon PLC IJFFebruary 6, 2024 | morningstar.comMGreen Mining Innovation: Neuer Chief Financing OfficerJanuary 14, 2024 | finanznachrichten.deGreen Mining Innovation: New Chief Financing OfficerJanuary 13, 2024 | finanznachrichten.dePermira Hires Maschmeyer From Vistria for Health-Care InvestingJanuary 4, 2024 | msn.com3 high-growth penny stocks to consider buying for 2024December 31, 2023 | msn.comSee More Headlines ERGO Stock Analysis - Frequently Asked Questions How were Ergomed's earnings last quarter? Ergomed plc (LON:ERGO) issued its quarterly earnings results on Monday, September, 18th. The company reported $1.20 earnings per share for the quarter. The company earned $22.91 million during the quarter. Ergomed had a trailing twelve-month return on equity of 18.08% and a net margin of 9.87%. How do I buy shares of Ergomed? Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Ergomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ergomed investors own include AbbVie (ABBV), FuelCell Energy (FCEL), Frontier Developments (FDEV), Future (FUTR), Lloyds Banking Group (LLOY) and NIO (NIO). Company Calendar Last Earnings9/18/2017Today5/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolLON:ERGO CIKN/A Webwww.ergomedplc.com Phone+44-1483-503205FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 0.29 Trailing P/E Ratio4,641.38 Forward P/E RatioN/A P/E GrowthN/ANet Income£15 million Net Margins9.87% Pretax MarginN/A Return on Equity18.08% Return on Assets10.16% Debt Debt-to-Equity Ratio3.32 Current Ratio1.79 Quick Ratio1.22 Sales & Book Value Annual Sales£152.09 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow54.67 Book ValueGBX 179 per share Price / BookN/AMiscellaneous Outstanding Shares52,080,000Free FloatN/AMarket Cap£701.00 million OptionableNot Optionable Beta0.79 The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (LON:ERGO) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersOne coin wired into Elon's visionThe Kevin Warsh Fed takeover is here. And he's brought a thesis with him that almost nobody is talking about. ...Crypto 101 Media | SponsoredIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | SponsoredSpaceX IPO Warning: Before you buy any SpaceX shares, read this.The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ergomed plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ergomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
